Prucalopride

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Prucalopride	Purity：98% min
CAS NO：179474-81-8	Solubility：DMSO: ≥ 31 mg/mL
Molecular Formula：C₁₈H₂₆ClN₃O₃	Package：Package according to customer requirements.
Molecular Weight：367.87	Storage：Store at -20℃

Quality control

COA

Remarks

Prucalopride (R093877) is a drug acting as a selective, high affinity 5-HT4 receptor agonist(pKi=8.6/8.1 for 5-HT4a/4b); >150-fold higher affinity for 5-HT4 receptors than for other receptors. IC50 value: 8.6/8.1 for 5-HT4a/4b(pKi) Target: 5-HT4 receptor Prucalopride is a novel enterokinetic compound and is the first representative of the benzofuran class. Receptor binding data have demonstrated prucalopride's high affinity to both investigated 5-HT(4) receptor isoforms, with mean pK(i) estimates of 8.60 and 8.10 for the human 5-HT(4a) and 5-HT(4b) receptor, respectively. From the 50 other binding assays investigated in this study only the human D(4) receptor (pK(i) 5.63), the mouse 5-HT(3) receptor (pK(i) 5.41) and the human sigma(1) (pK(i) 5.43) have shown measurable affinity, resulting in at least 290-fold selectivity for the 5-HT(4) receptor.

5-HT Receptor Antagonists Related Products:

Prucalopride Succinate; Agomelatine; Blonanserin; Azasetron HCl; Dolasetron mesylate; Palonosetron hydrochloride; Lurasidone; Intepirdine; SB 271046 HCL; Mirtazapine

References

[1]. Briejer MR, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001 Jun 29;423(1):71-83.

[2]. Emmanuel AV, et al. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther. 2012 Jan;35(1):48-55.